CAJ | 학술논문

目的：探讨氯氮平联合利培酮治疗难治性精神分裂症的临床疗效和安全性。方法将118例难治性精神分裂症患者按入院的先后顺序分为2组：观察组和对照组，每组59例。2组均采用氯氮平片治疗。在此基础上，观察组加用利培酮片治疗。观察2组临床疗效以及不良反应发生的情况，并对2组治疗前及治疗2、4、8和12周后采用阳性与阴性症状量表（PANSS）进行评分。结果2组治疗8、12周后 PANSS 得分均较治疗前明显降低（均 P ＜0．05），观察组治疗8、12周后 PANSS 得分均较对照组下降更明显（均 P ＜0．05）。观察组总有效率明显高于对照组（96．6％比81．4％，P ＜0．05），不良反应发生率明显低于对照组（15．3％比27．1％，P ＜0．05）。结论氯氮平联合利培酮治疗难治性精神分裂症疗效确切，安全、可靠，不会增加不良反应，可作为临床治疗难治性精神分裂症患者的方法之一。
목적：탐토록담평연합리배동치료난치성정신분렬증적림상료효화안전성。방법장118례난치성정신분렬증환자안입원적선후순서분위2조：관찰조화대조조，매조59례。2조균채용록담평편치료。재차기출상，관찰조가용리배동편치료。관찰2조림상료효이급불량반응발생적정황，병대2조치료전급치료2、4、8화12주후채용양성여음성증상량표（PANSS）진행평분。결과2조치료8、12주후 PANSS 득분균교치료전명현강저（균 P ＜0．05），관찰조치료8、12주후 PANSS 득분균교대조조하강경명현（균 P ＜0．05）。관찰조총유효솔명현고우대조조（96．6％비81．4％，P ＜0．05），불량반응발생솔명현저우대조조（15．3％비27．1％，P ＜0．05）。결론록담평연합리배동치료난치성정신분렬증료효학절，안전、가고，불회증가불량반응，가작위림상치료난치성정신분렬증환자적방법지일。
Objective To explore the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia.Methods A total of 118 patients with refractory schizophrenia were randomly treated with clozapine tablets alone(control group,n = 59)or in combination with risperidone tablets(observation group,n=59).Clinical efficacy and adverse re-actions were observed in both groups.Patients were scored using the Positive and Negative Syn-drome Scale(PANSS)before and after treatment for 2,4,8 and 12 weeks.Results PANSS scores significantly decreased in both groups after treatment for 8 and 12 weeks(P <0.05),and the de-crease in observation group was more obvious than that in control group(P <0.05).In addition, the total effective rate in observation group was significantly higher than that in control group (96.6% vs 81.4%,P < 0.05),and the incidence of adverse reactions in observation group was significantly lower than that in control group(15.3% vs 27.1%,P < 0.05).Conclusion The combination of clozapine and risperidone is an effective,safe and reliable treatment and can reduce adverse reactions in the treatment of refractory schizophrenia.